Industry news · event 2026-02-19 · 3 min read
The February 2026 Warning-Letter Wave: FDA Puts ~30 Telehealth Sellers on Notice
In one coordinated action, the FDA sent roughly thirty warning letters over compounded GLP-1 marketing — approval-implying claims, equivalence language, and safety-claim overreach — resetting how the industry talks.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answerIn one coordinated action, the FDA sent roughly thirty warning letters over compounded GLP-1 marketing — approval-implying claims, equivalence language, and safety-claim overreach — resetting how the industry talks.
The FDA's patience with compounded-GLP-1 marketing ended in February 2026, when the agency issued a coordinated wave of roughly thirty warning letters to telehealth companies and sellers — the largest single enforcement action in the category's history.
The letters' common threads were rhetorical, not chemical: language implying FDA approval of compounded products, equivalence claims ("same as Zepbound/Wegovy"), safety-and-efficacy assertions borrowed from the approved products' trials, and in some cases the marketing of frank counterfeits or research-grade material. The message was that the words around compounded GLP-1s are regulated territory, not just the vials.
The market's response is visible across our database: quieter equivalence language, more "not FDA-approved" disclosures, and several brand-only pivots by major names in the following weeks. Follow-on letters over promotional presentation — marketing claims and logo/labeling treatment on vials — continued reaching telehealth platforms across the industry into mid-2026, an essentially category-wide correction rather than a verdict on any one program. Our editorial rule predates the wave and matches it: trial numbers belong to the approved products that generated them, and our reviews say so on every page.